Seeking Alpha25d
Pfizer gets FDA accelerated approval for Braftovi
Pfizer (NYSE:PFE) has received FDA accelerated approval for its drug Braftovi in combination with other therapies as a first-line treatment for metastatic colorectal cancer, or mCRC, with a BRAF ...
Seeking Alpha22d
Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked
Pfizer recently received accelerated approval for its Braftovi drug, a treatment for metastatic colorectal cancer. All these drugs have come from years of R&D investments and capital that has been ...
Morningstar25d
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
“For more than a decade, Pfizer has been a pioneer in delivering targeted therapies for molecular-driven cancers. With today’s accelerated approval of the BRAFTOVI regimen, patients with ...
Pharm Exec23d
FDA Grants Accelerated Approval to Pfizer’s Braftovi Combination for Metastatic Colorectal Cancer
The FDA has granted accelerated approval to Pfizer’s Braftovi (encorafenib) in combination with cetuximab and mFOLFOX6 for the treatment of patients with metastatic colorectal cancer (mCRC) harboring ...
Yahoo Finance23d
Pfizer’s colorectal cancer combo therapy gains accelerated approval from FDA
Pfizer has gained accelerated approval from the US Food and Drug Administration (FDA) for BRAFTOVI (encorafenib) in conjunction with cetuximab and mFOLFOX6 for treating metastatic colorectal ...
Pharmabiz22d
Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer
Pfizer Inc announced that the US Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil, leucovorin, and ...
Zacks.com on MSN11d
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?
Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in ...
MarketWatch25d
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment
Pfizer said Friday that the Food and Drug Administration approved its treatment for patients with metastatic colorectal cancer. The FDA approved braftovi in combination with cetuximab and mFolfox6 ...
Yahoo Finance26d
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK, December 20, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI ® (encorafenib) in combination with ...
Eagle-Tribune26d
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI ® (encorafenib) in combination with cetuximab (marketed as ERBITUX ® ) and mFOLFOX6 ...
Stockhouse26d
U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and ...